Trial | NCT00273429  Report issue

Title

Cosopt Versus Xalatan

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    dorzolamide latanoprost timolol ...

  • Study Participants

    None
To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.
Study Started
Apr 30
2005
Study Completion
Dec 31
2005
Last Update
Jan 09
2007
Estimate

Drug timolol maleate 0.5%

Drug dorzolamide/timolol maleate fixed combination

Drug latanoprost 0.005%

Drug placebo

Criteria 

Inclusion Criteria:

adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion Criteria:

any contraindications to study medications
any anticipated change in systemic hypertensive therapy during the trial
No Results Posted